Leerink Partners Maintains a Buy on Madrigal Pharmaceuticals (MDGL), Here’s Why

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is one of the Best Mid Cap Growth Stocks to Buy According to Hedge Funds. On August 19, Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced receiving a conditional marketing authorization for Rezdiffra from the European Commission. Rezdiffra treats adults with noncirrhotic MASH and moderate to advanced liver fibrosis. Wall Street has been bullish on the stock, and the stock has surged more than 8.5% since the announcement.

Recently, on August 20, Leerink Partners analyst Thomas Smith maintained a Buy rating on Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) without disclosing any price target. The analyst noted that the approval is important because it allows treatment for noncirrhotic MASH without needing a biopsy. Moreover, Rezdiffra is now the first and only therapy approved for MASH in Europe and also fits well with the European treatment guidelines.

Leerink Partners Maintains a Buy on Madrigal Pharmaceuticals (MDGL), Here's Why

Management also plans to start selling the treatment in Germany and then expand across Europe.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a biotechnology company that develops treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease.

While we acknowledge the potential of MDGL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MDGL and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.